Guest Columns & From The Editor

  1. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

    Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around. 

  2. August 2025 — CDMO Opportunities And Threats Report 9/11/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  3. How AbbVie's Digital Transformation Brought Platform Knowledge Closer 9/9/2025

    A custom-built digital ecosystem reduced the time spent on documentation in AbbVie's bioprocess development labs by about 70% for some experiment types.

  4. Optimizing Lentiviral Vectors For Allogeneic CAR-T Manufacturing 9/5/2025

    A group of graduate researchers explored VSV-G affinity chromatography as an alternative to the standard anion exchange chromatography or AEX.

  5. Contract Manufacturing Outsourcing Trends For Advanced Therapies In 2025 And Beyond 9/4/2025

    Contract manufacturing continues to emerge as the widely adopted model for bringing cell therapies, gene therapies, RNA therapeutics, and oligonucleotides to patients worldwide.

  6. Building The Biopharma Manufacturing Facility Of The Future Requires A Phased IT/OT Strategy 9/4/2025

    Your pharma or biotech company can take these actionable steps to achieve digital facility operations and successfully build your own facility of the future. 

  7. New Group Wants 'Phase-Appropriate' Thinking To Retire 9/4/2025

    Decisions in cell and gene therapy are not about aligning with arbitrary clinical phases but about balancing risk.

  8. Using Slot Management To Bridge The Gap Between Capacity And CGTs 9/3/2025

    Optimizing slot management is essential for cell and gene therapy manufacturers to overcome high costs, long turnaround times, and limited patient access by enabling real-time scheduling, better resource utilization, and advanced technology integration.

  9. Lilly's Exploring A Universal AAV Purification Method 9/2/2025

    Serotype-specific resins don't scale gracefully. One team at Eli Lilly and Company is exploring an alternative that skips affinity resins altogether.

     

  10. FDA Report Details FY24 Inspections, Shows Big Uptick In Key Countries 8/29/2025

    The 2024 Report on the State of Pharmaceutical Quality shows the agency's efforts to normalize post-pandemic oversight under the previous administration.